Compare American Express Co (AXP) vs Novavax Inc (NVAX) Price & Performance

AXP trades at $341.25, up 0.7% on the day, with a bullish technical signal and strong support at $339. Revenue grew to $72.23B in 2025, with net income of $10.83B and a 15.07% net margin. Recent earnings beat expectations in Q1 and Q2 2026, while analyst consensus is a Buy with a $369.42 price target. News highlights Amex Ventures' AI investments and premium cardmember perks.

Outlook is positive given earnings momentum and strategic AI bets, but risks include rising debt levels and competitive pressure. The stock offers growth potential with a reasonable P/E of 20.68, though investors should watch for economic sensitivity in consumer spending.

Novavax (NVAX) trades at $7.97, up 1.01% with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported strong Q2 2026 results, beating revenue and earnings estimates while raising full-year guidance. Despite negative profitability metrics, valuation ratios appear attractive with P/E of 3.14 and EV/EBITDA of 1.72. Recent news highlights progress with Sanofi partnership and cost reduction initiatives.

The outlook remains challenged by negative cash flows and accumulated deficits, but analyst sentiment is positive with 74% buy ratings. Key risks include ongoing operational losses and vaccine demand volatility, while potential upside exists from partnership milestones and adjuvant platform expansion. The stock presents a high-risk opportunity with significant analyst support despite fundamental weaknesses.